Healthcare
Organigram Global Inc.(OGI)
Live Price
Offline$1.06
-1.85% today
1Y Change
-28.42%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $260.00M
- Revenue Growth
- +16.4%
- EPS Growth
- +70.8%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Organigram Global Inc. (OGI) is a Healthcare stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $1.06 and down 28.4% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +16.4%, EPS growth of +70.8%, a dividend yield of 0.0%. What stands out right now is revenue +16.4%, EPS +70.8%, free cash flow -1027.1% with operating margin -28.7% and ROIC -18.4%. Valuation is more restrained than many high-expectation growth names at P/E 14.3 and price/sales 0.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines OGI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.4% vs +7.6% peer median
Operating Margin
Below sector median
-28.7% vs +19.4% peer median
P/E
Below sector median
14.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.4% and EPS at +70.8%, with operating margin around -28.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -15.3% | -19.5% | -17.6% |
2026 Feb 10, 2026 | -100.0% | -5.8% | -0.7% | +8.6% |
2025 Dec 16, 2025 | -4058.0% | +7.7% | -11.2% | -17.9% |
Benchmark Edge
OGI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OGI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OGI Max Drawdown
-55.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OGI and SPY.
Company Overview
Organigram Global Inc.
NASDAQ Global Select
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
- Leadership
- James H. Yamanaka
- IPO Date
- May 21, 2019
- Employees
- 1.1k
- Street Address
- 35 English Drive
- Mailing
- Moncton, NB, E1E 3X3
- Region
- Moncton, NB, CA
- Reporting Currency
- USD
- Investor Line
- 15063841571
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.3
- EV/EBITDA
- โ
- Price/Sales
- 0.9
- Price/Book
- 0.7
Growth
- Revenue
- +16.4%
- EPS
- +70.8%
- Free Cash Flow
- -1027.1%
Profitability
- Gross Margin
- 6.8%
- Operating Margin
- -28.7%
- Net Margin
- 6.5%
- ROE
- 4.9%
- ROIC
- -18.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.